These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29521477)

  • 1. Serial intravascular ultrasound evaluation of the DESolve™ novolimus-eluting bioresorbable coronary scaffold system.
    Barreira G; Costa JR; Costa R; Staico R; Chamie D; Slhessarenko JR; Tanajura LF; Abizaid A; Sousa A; Abizaid A
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):E368-E374. PubMed ID: 29521477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
    Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
    JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter post-marketing evaluation of the Elixir DESolve
    Nef H; Wiebe J; Boeder N; Dörr O; Bauer T; Hauptmann KE; Latib A; Colombo A; Fischer D; Rudolph T; Foin N; Richardt G; Hamm C
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):1021-1027. PubMed ID: 29508518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.
    Wu Y; Shen L; Ge L; Wang Q; Qian J; Zhang F; Yao K; Huang D; Chen Y; Ge J
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():630-7. PubMed ID: 26864162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
    Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Plaque Composition, Morphology, and Burden on DESolve Novolimus-Eluting Bioresorbable Vascular Scaffold Expansion and Eccentricity - An Optical Coherence Tomography Analysis.
    Boeder NF; Dörr O; Bauer T; Elsässer A; Möllmann H; Achenbach S; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2019 Jun; 20(6):480-484. PubMed ID: 30638889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
    Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First in human evaluation of the vascular biocompatibility and biomechanical performance of a novel ultra high molecular weight amorphous PLLA bioresorbable scaffold in the absence of anti-proliferative drugs: Two-year imaging results in humans.
    Moncada M; Delgado JA; Colombo A; Gasior P; Ramzipoor K; Estrada A; Lee C; Dokko D; Granada JF
    Catheter Cardiovasc Interv; 2018 Sep; 92(3):E246-E253. PubMed ID: 29243353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities.
    Simsek C; Karanasos A; Magro M; Garcia-Garcia HM; Onuma Y; Regar E; Boersma E; Serruys PW; van Geuns RJ
    EuroIntervention; 2016 Jan; 11(9):996-1003. PubMed ID: 25349042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial invasive imaging follow-up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold.
    Tovar Forero MN; van Zandvoort L; Masdjedi K; Diletti R; Wilschut J; de Jaegere PP; Zijlstra F; Van Mieghem NM; Daemen J
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):226-231. PubMed ID: 31033171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
    Wiebe J; Dörr O; Ilstad H; Husser O; Liebetrau C; Boeder N; Bauer T; Möllmann H; Kastrati A; Hamm CW; Nef HM
    JACC Cardiovasc Interv; 2017 Mar; 10(5):477-485. PubMed ID: 28216214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial intravascular ultrasound analysis of complex bifurcation coronary lesions treated with the Tryton Bifurcation Stent in conjunction with an everolimus-eluting stent: IUVANT (Intravascular Ultrasound Evaluation of Tryton Stent) study.
    Bartorelli AL; Trabattoni D; Almonacid A; Fabbiocchi F; Montorsi P; Galli S; Grancini L; Ravagnani P; Mintz GS; Kaplan AV; Popma JJ; Maehara A
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):544-53. PubMed ID: 25115944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Accuracy of Coronary CT Angiography for the Evaluation of Bioresorbable Vascular Scaffolds.
    Collet C; Chevalier B; Cequier A; Fajadet J; Dominici M; Helqvist S; Van Boven AJ; Dudek D; McClean D; Almeida M; Piek JJ; Tenekecioglu E; Bartorelli A; Windecker S; Serruys PW; Onuma Y
    JACC Cardiovasc Imaging; 2018 May; 11(5):722-732. PubMed ID: 28734923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
    Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
    Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DESolve novolimus-eluting bioresorbable coronary scaffold failure assessed by frequency-domain optical coherence tomography imaging.
    Porto I; Vergallo R; Sangiorgi GM; Burzotta F; Garbo R; D'Amario D; Trani C; Rebuzzi AG; Crea F
    Coron Artery Dis; 2016 Jun; 27(4):334-6. PubMed ID: 26882020
    [No Abstract]   [Full Text] [Related]  

  • 20. Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial.
    Seth A; Onuma Y; Chandra P; Bahl VK; Manjunath CN; Mahajan AU; Kumar V; Goel PK; Wander GS; Kaul U; Ajit Kumar VK; Abizaid A; Serruys PW
    EuroIntervention; 2019 Sep; 15(7):607-614. PubMed ID: 31147308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.